公开(公告)号：WO2022035828A1

公开(公告)日：2022-02-17

申请号：PCT/US2021/045350

申请日：2021-08-10

申请人： HORIZON THERAPEUTICS IRELAND DAC

发明人： PELOSO, Paul ,  LAMOREAUX, Brian ,  VERMA, Swarnendra

IPC分类号： A61P19/06 ,  A61K38/44 ,  A61K47/60 ,  A61K31/505

摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase in a shortened infusion period less than 120 minutes and a shortened infusion volume of less than 250 mL. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

公开(公告)号：WO2022269346A2

公开(公告)日：2022-12-29

申请号：PCT/IB2022/000337

申请日：2022-06-17

申请人： HORIZON THERAPEUTICS IRELAND DAC

发明人： BROWN, Duncan ,  NYBORG, Andrew ,  BOWERS, Michael, Scott

IPC分类号： C12N15/113 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/32 ,  C12N2310/351 ,  C12Y117/01004

摘要： Compositions, methods for making and using polynucleotide inhibitors modulating xanthine dehydrogenase expression or activity are provided.

公开(公告)号：WO2021202955A

公开(公告)日：2021-10-07

申请号：PCT/US2021/025505

申请日：2021-04-02

申请人： HORIZON THERAPEUTICS IRELAND DAC [IE]/[IE]

发明人： PELOSO, Paul ,  ALI, Farah

IPC分类号： C07D209/42

摘要： Provided is a method of treating systemic sclerosis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound 1), or a pharmaceutically acceptable salt thereof, for a dosing period of at least about 24 consecutive weeks.

公开(公告)号：WO2022187510A1

公开(公告)日：2022-09-09

申请号：PCT/US2022/018737

申请日：2022-03-03

申请人： HORIZON THERAPEUTICS IRELAND DAC ,  SHERMAN, Jeffrey W.

发明人： SHERMAN, Jeffrey W.

IPC分类号： A61K39/395

摘要： Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

公开(公告)号：WO2021243014A1

公开(公告)日：2021-12-02

申请号：PCT/US2021/034506

申请日：2021-05-27

申请人： HORIZON THERAPEUTICS IRELAND DAC ,  KORN, Bobby

发明人： SHERMAN, Jeffrey

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/32

摘要： Provided herein are methods of treating or reducing idiopathic orbital inflammation (IOI), also known as idiopathic orbital inflammatory syndrome, nonspecific orbital inflammation (NSOI), orbital inflammatory pseudotumor, and orbital inflammatory syndrome (OIS), or one or more symptoms thereof, in a subject with IOI, comprising administering to the subject an effective amount of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, and pharmaceutical composition comprising an amount of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor effective for treating or reducing one or more effects of idiopathic orbital inflammation (IOI), or one or more symptoms thereof, in a subject with IOI.